AstraZeneca Annual Report and Form 20-F Information 2011

14 Interest-bearing loans and borrowingsRepaymentdates2011$m2010$m2009$mCurrent liabilitiesBank overdrafts On demand 137 87 904.625% Non-callable bond Euros 2010 – – 1,0735.625% Non-callable bond Euros 2010 – – 7175.4% Callable bond US dollars 2012 1,769 – –Other loans Within one year 84 38 461,990 125 1,926Non-current liabilities5.4% Callable bond US dollars 2012 – 1,800 1,8055.4% Callable bond US dollars 2014 834 837 8215.125% Non-callable bond Euros 2015 969 993 1,0725.9% Callable bond US dollars 2017 1,896 1,855 1,8187% Guaranteed debentures US dollars 2023 387 359 3465.75% Non-callable bond Pounds sterling 2031 536 535 5586.45% Callable bond US dollars 2037 2,716 2,718 2,7177,338 9,097 9,137All loans and borrowings above are unsecured.15 Financial instrumentsDerivative financial instrumentsSet out below is a summary of the derivative financial instruments included in the consolidated statement of financial position at 31 December2011, 31 December 2010 and 31 December 2009.Non-currentassets$mCurrentassets$mCurrentliabilities$mDesignated in a fair value hedge 153 20 – 173Related to instruments designated at fair value through profit or loss 189 – – 189Other derivatives – 5 (9) (4)31 December 2011 342 25 (9) 358Total$mNon-currentassets$mDesignated in a fair value hedge 164 – – 164Related to instruments designated at fair value through profit or loss 160 – – 160Other derivatives – 9 (8) 131 December 2010 324 9 (8) 325Currentassets$mCurrentliabilities$mTotal$mNon-currentassets$mDesignated in a fair value hedge 135 – – 135Related to instruments designated at fair value through profit or loss 127 – – 127Other derivatives – 24 (90) (66)31 December 2009 262 24 (90) 196Currentassets$mCurrentliabilities$mTotal$mFinancial StatementsAstraZeneca Annual Report and Form 20-F Information 2011 Financial Statements 161